Fluoxetine treatment of depressed patients with comorbid anxiety disorders
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Major depression with comorbid anxiety disorder is associated with poor antidepressant outcome compared to major depression without comorbid anxiety disorder. The purpose of our study was to assess changes in severity of both depressive and anxiety symptoms in outpatients with major depression with comorbid anxiety disorder following fluoxetine treatment. We enrolled 123 outpatients (mean age 38.9 ± 10.8 years; 49% women) with major depressive disorder accompanied by one or more current comorbid anxiety disorders in our study. Patients were treated openly with fluoxetine 20 mg/day for 8 weeks. Efficacy assessments included the 17-item Hamilton Rating Scale for Depression (HAM-D) and the patient-rated Symptom Questionnaire (SQ) Scales for Depression and Anxiety. The mood and anxiety disorder modules of the Structured Clinical Interview for DSM-III-R were administered at screen and endpoint. We used ‘intent to-treat’ analysis in examining all patients assigned to treatment and completing the baseline visit. The mean number of comorbid anxiety disorders per patient was 1.5 ± 0.68. The mean HAM-D-17 score and mean Clinical Global Impressions-Severity scores decreased significantly from baseline to endpoint (week 8) following fluoxetine treatment (p < 0.0001). There were significant decreases in all four SQ scale scores, from baseline to endpoint: depression, anxiety, somatic symptoms and anger-hostility (p < 0.0001). Fifty-three percent of patients (n = 65) were depression responders (i.e. ≥ 50% decrease in HAM-D-17 score at endpoint) and 46% (n = 57) were remitters (HAM-D-17 ≤ 7 at endpoint). Patients with panic disorder had significantly higher baseline HAM-D-17 scores compared to those without panic disorder (p< 0.01). Patients with comorbid obsessive–compulsive disorder (OCD) were significantly less likely to be responders to fluoxetine at endpoint (≥ 50% decrease in HAM-D-17) and to be remitters (HAM-D-17 score of ≤ 7 at endpoint) compared to patients without comorbid OCD (p < 0.01). Of the 41 patients on whom endpoint Structured Clinical Interview for DSM-III-R modules for anxiety disorders were available, 49% (n = 20) no longer met criteria for one or more of their anxiety disorder diagnoses at endpoint. Our preliminary findings suggest that fluoxetine is effective in treating outpatients with major depression with comorbid anxiety disorders, with a significant effect on both depression and anxiety symptoms. Further double-blind, placebo-controlled trials are required in larger samples to confirm our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders
Regier, D. A., Rae, D. S., Narrow, W. E., Kaelber, C. T., & Schatzberg, A. F. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000293483 · Cited by 407
Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders.
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.10.1293 · Cited by 312 · cited 5×
“Introduction Major depressive disorder (MDD) accompanied by comorbid anxiety disorders is characterized by distinct pathophysiology, course and treatment response (Hiller et al., 1989; Brown et al., 1996; Fava et al., 1997).”
BackgroundInfluentialMajor depressive subtypes and treatment response
Fava, M., Uebelacker, L. A., Alpert, J. E., Nierenberg, A. A., Pava, J. A., & Rosenbaum, J. F. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00440-4 · Cited by 247
Self-citationSuicidal Ideation in Major Depression: Sex Differences and Impact of Comorbid Anxiety
Schaffer, A., Levitt, A. J., Bagby, R. M., Kennedy, S. H., Levitan, R. D., & Joffe, R. T. (2000) · The Canadian Journal of Psychiatry · doi:10.1177/070674370004500906 · Cited by 67
CORNE, S. J., & HALL, J. R. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198907000-00007 · Cited by 39
Marchesi, C., Ceccherininelli, A., Rossi, A., & Maggini, C. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979331 · Cited by 24
Cited by
BELZER, K., & SCHNEIER, F. R. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200409000-00003 · Cited by 235
Kim, C. S., Chang, P. Y., & Johnston, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.027 · Cited by 158
Wexler, T., Gunnell, L., Omer, Z., Kuhlthau, K., Beauregard, C., Graham, G., Utz, A. L., Biller, B., Nachtigall, L., Loeffler, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2671 · Cited by 69
Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial
Cook, J. W., Spring, B., McChargue, D. E., Borrelli, B., Hitsman, B., Niaura, R., Keuthen, N. J., & Kristeller, J. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1711-8 · Cited by 46
Anxiety Disorders and Depression Comorbidity
Huppert, J. D. (2008) · Oxford Handbooks Online · doi:10.1093/oxfordhb/9780195307030.013.0044 · Cited by 37
Metadata
- Authors
- Sonawalla, S. B., Farabaugh, A., Johnson, M. W., Morray, M., Delgado, M. L., Pingol, M. G., Rosenbaum, J. F., & Fava, M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2002-05
- Volume
- 16
- Issue
- 3
- Pages
- 215-219
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1986638237
- Cited by
- 23
- References
- 7
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluoxetine treatment of depressed patients with comorbid anxiety disorders. https://app.cochat.ai/papers/10.1177/026988110201600304
- The paper
- Sonawalla, S. B., Farabaugh, A., Johnson, M. W., Morray, M., Delgado, M. L., Pingol, M. G., Rosenbaum, J. F., & Fava, M. (2002). Fluoxetine treatment of depressed patients with comorbid anxiety disorders. Journal of Psychopharmacology. https://doi.org/10.1177/026988110201600304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.